je.st
news
Tag: patients
Blue Bell recalls products after three patients die of food poisoning
2015-03-16 01:00:00| Food Processing Technology
Texas-based Blue Bell ice cream has recalled its products for the first time in 108 years after three deaths were reported from a foodborne illness linked to some of its ice cream products.
KEYTRUDA (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Scheme (EAMS) for Advanced Melanoma
2015-03-11 01:01:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. EAMS Aims to Give U.K. Patients Access to Promising, Innovative Treatments Prior to European License KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the companys anti-PD-1 therapy, pembrolizumab, which is marketed in the U.S. under the name KEYTRUDA, is the first treatment to be accepted under the U.K.s new Early Access to Medicines Scheme (EAMS). Pembrolizumab was accepted under the scheme for the treatment of advanced melanoma based on the significance of the early study findings and unmet medical need. Language: English Contact: MerckMedia Contacts:Pam Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestor Contacts:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease
2015-03-05 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. These and other post-hoc subgroup analyses from TRA-2°P are being presented at the 2015 American College of Cardiology Scientific Sessions KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial of ZONTIVITY (vorapaxar), one of the largest secondary prevention studies of an antiplatelet medicine. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
added
study
reduced
Hackers develop apps to help MS patients
2015-02-10 20:52:48| Biotech - Topix.net
Jeri Burtchell of Florida and Matt Winslow of North Carolina took home the $20,000 top prize at last weekend's Hack MS event, sponsored by Biogen Idec. Several other teams took home cash prized for their efforts as well.
Tags: develop
patients
apps
hackers
Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients
2015-02-09 15:30:43| Biotech - Topix.net
Oncolytics Biotech Inc. today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration for REOLYSIN for the treatment of high grade gliomas in pediatric patients. Oncolytics has conducted three previous clinical studies in brain cancers including gliomas, and has found that REOLYSIN can infect a variety of brain tumors when delivered intravenously.
Tags: high
drug
grade
patients
Sites : [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] next »